HB3833 creates the Oklahoma Autologous and Directed Blood Donation Act, a new framework for handling patient-specific blood donations. The bill defines key terms such as autologous donation, directed donation, hospital, blood bank, and physician, and then requires hospitals and blood banks to honor a physician’s written order for a patient to use autologous or directed blood for a scheduled medical procedure, so long as donor eligibility, timing, and availability requirements are met.
The measure also assigns operational duties to hospitals and blood establishments. Hospitals must permit these donations when ordered, coordinate with blood banks for labeling, storage, and timely availability, and may not refuse them solely because of internal policy if the statutory conditions are satisfied. Blood banks must collect, process, store, and track these units according to applicable standards, while both hospitals and blood banks may charge reasonable administrative fees for the extra handling involved. The bill includes liability protections when a requested unit is unavailable for specified reasons, such as donor ineligibility, failed safety testing, expiration, or circumstances beyond the facility’s control.
HB3833 would add new provisions to Title 63 of the Oklahoma Statutes, specifically creating Sections 2160 through 2160.6, and directs the State Department of Health to adopt implementing rules within 180 days of the effective date. Those rules are limited so they cannot impose requirements beyond existing federal blood-handling standards, and the department must consult with hospitals, blood establishments, physicians, and other stakeholders. The bill is set to take effect November 1, 2026.
The bill’s overall sentiment appears neutral to favorable based on its structure and lack of recorded opposition in the provided materials. Its purpose is to formalize and standardize access to patient-directed blood donations, which may be viewed as improving patient choice and planning for scheduled procedures. At the same time, the bill anticipates operational burdens by allowing administrative fees and limiting liability, suggesting an attempt to balance patient access with facility logistics and safety requirements.
The main points of potential contention are likely to involve hospital and blood bank compliance obligations, the 72-hour advance request requirement, and whether the bill could create workflow or inventory challenges for facilities. Another possible issue is the restriction on the Department of Health from imposing requirements beyond existing federal standards, which may be seen as limiting regulatory flexibility. No committee debate or votes were provided, so there is no recorded partisan or stakeholder opposition in the available history.
The bill would create a new statutory scheme in Title 63 governing autologous and directed blood donations, requiring hospitals and blood banks to accommodate physician-ordered patient-specific blood use under defined conditions. It would impose duties on facilities for collection, processing, storage, labeling, tracking, coordination, and disclosure of administrative fees, while also providing liability protections for nonavailability in specified circumstances. The Oklahoma State Department of Health would be required to promulgate implementing rules, but only within the bounds of existing federal blood-handling standards.
No committee transcript or vote record was provided, so there is no direct evidence of legislative debate or opposition. Based on the bill text, the measure appears generally supportive of patient access to autologous and directed blood donations while also protecting hospitals and blood banks through eligibility, timing, fee, and liability provisions. The overall tone is pragmatic and administrative rather than controversial.
Potential areas of contention include whether hospitals and blood banks should be required to honor physician orders for directed or autologous donations, especially when doing so may complicate scheduling, inventory, or compliance workflows. Facilities may also be concerned about the 72-hour advance notice requirement, the costs of special handling, and the extent to which the bill limits their discretion by prohibiting denial based solely on internal policy. On the other hand, patients and physicians seeking greater control over transfusions would likely support the bill’s access requirements and coordination mandates.